Skip to main content
Biotest AG logo

Biotest AG — Investor Relations & Filings

Ticker · BIO3 ISIN · DE0005227201 LEI · 529900JVX7RPXBLYUD89 F Manufacturing
Open in API
Filings indexed 1,148 across all filing types
Latest filing 2018-03-22 Investor Presentation
Country DE Germany
Listing F BIO3

About Biotest AG

https://www.biotest.com/de/en/index.cfm

Biotest AG is a global company that develops, manufactures, and supplies plasma protein products and biotherapeutic drugs. Sourced from human blood plasma, its products are primarily used in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. The portfolio includes immunoglobulins (e.g., Intratect), coagulation factors, and albumins designed to treat severe and chronic diseases such as immune deficiencies, haemophilia, and coagulation disorders. The company manages the entire value chain from clinical development to sales and is advancing a pipeline of new treatments, including next-generation immunoglobulins (BT595) and fibrinogen concentrates (BT524). Biotest also provides Human Serum Albumin for use as a multifunctional excipient in pharmaceutical and diagnostic applications.

Recent filings

Filing Released Lang Actions
Investor Presentation 2018
Investor Presentation Classification · 95% confidence The document is titled "Press and Analyst Conference FY 2017 Frankfurt/Main, 22 March 2018" and contains detailed financial tables, income statements, balance sheets, cash flow summaries, guidance for 2018, and strategic pillars. The content clearly summarizes the full fiscal year (FY) 2017 performance and outlook. Although it is a presentation/conference material, the depth and scope of the financial review strongly suggest it is related to the Annual Report (10-K) or a comprehensive Investor Presentation (IP) covering the full year. Given the structure, which includes detailed financial breakdowns and guidance, it functions as a comprehensive review of the year's results, often presented alongside or shortly after the official 10-K filing. However, since it is explicitly labeled as a 'Press and Analyst Conference' presentation, the most fitting category among the provided options that captures a detailed, strategic, and financial review presentation is 'Investor Presentation' (IP). It is too detailed to be just an 'Earnings Release' (ER) and is not the formal 10-K document itself, but a presentation summarizing it.
2018-03-22 English
Investor Presentation 2018
Investor Presentation Classification · 95% confidence The document is titled "Press and Analyst Conference FY 2017 Frankfurt/Main, 22 March 2018" and contains detailed financial tables, income statements, balance sheets, cash flow summaries, guidance for 2018, and strategic pillars. The content clearly summarizes the full fiscal year (FY) 2017 performance and outlook. Although it is a presentation/conference material, the depth and scope of the financial review strongly suggest it is related to the Annual Report (10-K) or a comprehensive Investor Presentation (IP) covering the full year. Given the structure, which includes detailed financial breakdowns and guidance, it functions as a comprehensive review of the year's results, often presented alongside or shortly after the official 10-K filing. However, since it is explicitly labeled as a 'Press and Analyst Conference' presentation, the most fitting category among the provided options that captures a detailed, strategic, and financial review presentation is 'Investor Presentation' (IP). It is too detailed to be just an 'Earnings Release' (ER) and is not the formal 10-K document itself, but a presentation summarizing it.
2018-03-22 German
Magazine for Annual Report 2017
Audit Report / Information Classification · 98% confidence The document is explicitly titled 'Magazine for Annual Report 2017' and contains a detailed Table of Contents listing sections like 'Financial Year 2017 Highlights', an 'Interview with the Board of Management', and extensive discussion of the past year's performance, strategic outlook, and major events (like the Creat merger and the Biotest Next Level project). The content structure, length (40,720 chars), and focus on comprehensive annual performance review strongly indicate this is the company's Annual Report, even if presented in a magazine format. It is not a short announcement (RPA/RNS) but the full report content itself. The presence of 'Financial Year 2017 Highlights' and detailed operational/financial discussions aligns best with the 10-K definition, which encompasses the full yearly report. FY 2017
2018-03-22 English
Magazin zum Geschäftsbericht 2017
Investor Presentation Classification · 85% confidence The document is titled 'Magazin zum Geschäftsbericht 2017' (Magazine for the 2017 Annual Report). It contains an interview with the board, highlights of the fiscal year, strategic outlook, and sustainability information. While it functions as a summary or magazine version of the annual report, it lacks the full audited financial statements required for a 10-K or IR classification. It serves as a supplementary communication piece to the annual report, which falls under the category of Investor Presentation or general corporate reporting. Given the structure and content, it is best classified as an Investor Presentation (IP) as it provides strategic context and highlights for investors. FY 2017
2018-03-22 German
Biotest AG: First patient with acquired fibrinogen deficiency treated in clinical phase III study of Biotest AG
Legal Proceedings Report Classification · 99% confidence The document is a press release dated March 15, 2018, announcing a clinical trial milestone: the first patient treated in a Phase III study for Biotest AG's fibrinogen concentrate. It details the study design (ADFIRST), regulatory coordination (EMA), and the intended use of the results for marketing authorization. This content relates to research and development progress, which is a key component of investor relations materials, but it is not a formal financial report (like 10-K or IR) nor a transcript (CT). Since it is an announcement about clinical research progress, it fits best under the general category of Investor Relations/Research Updates. Given the provided options, this type of announcement, focusing on clinical trial progress and regulatory steps, is often categorized broadly. It is not a standard Earnings Release (ER), Management Discussion (MDA), or a formal Audit Report (AR). It is a specific update on product development. In the absence of a dedicated 'Clinical Trial Update' code, and noting that it is a news release about R&D, it is closest to a general regulatory/corporate news item. However, since it details research updates, it is most appropriately classified as a general corporate announcement that is not covered by the other specific financial or governance codes. Given the options, and recognizing this is a research update announcement, it does not fit perfectly. If 'Research Update' were an option, it would be chosen. As a corporate news item detailing R&D progress, it falls under the general regulatory filing/news category, RNS, as it is disseminated via DGAP (a regulatory news service).
2018-03-15 English
Biotest AG: Biotest supports a large international registry study to record data on use of Pentaglobin(R) in patients with severe bacterial infections
Regulatory Filings Classification · 100% confidence The document is a press release dated March 13, 2018, announcing that Biotest AG is supporting a large international registry study (PERFORM) for its product Pentaglobin(R). It details the study's aim, scope, and provides general company information. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a comprehensive interim report (IR). It is an announcement about a clinical/scientific activity, which does not fit neatly into the specific financial or governance categories. Given the options, this type of general corporate news announcement, especially one related to clinical trials/studies that isn't a formal regulatory filing (like a press release distributed via DGAP), is best categorized as a general Regulatory Filing (RNS) or potentially a miscellaneous announcement, as it doesn't align with the specific definitions for ER, IR, AR, or MANG. Since it is a news announcement distributed via a service (DGAP), RNS serves as the most appropriate general regulatory/news fallback category.
2018-03-13 English

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.